UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 or 15(d) of the

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 1022, 2026

MOONLAKE IMMUNOTHERAPEUTICS

(Exact Name of Registrant as Specified in Its Charter)

Cayman Islands

001-39630

98-1711963

~~001-39630~~

~~98-1711963~~

(State or Other Jurisdictionof Incorporation)

(CommissionFile Number)

(IRS EmployerIdentification No.)

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

Dorfstrasse 29

6300 Zug

Switzerland

(Address of Principal Executive Offices and Zip Code)

41 415108022

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A ordinary share, par value $0.0001 per share		MLTX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 21.0201. ~~Results~~ ofEntry ~~Operations~~into ~~and~~a ~~Financial~~Material ~~Condition.~~Definitive Agreement

On May 10 22, 2026, MoonLake Immunotherapeutics (the “Company”) ~~issued~~entered into a ~~press~~Master ~~release~~Commercial ~~announcing~~Supply ~~its~~Agreement ~~financial~~(the ~~results~~“Vetter MCSA”) ~~for~~with Vetter Pharma International GmbH (“Vetter”). Pursuant to the ~~quarter~~Vetter ~~ended~~MCSA, ~~March 31~~Vetter, ~~2026~~through Vetter Pharma-Fertigung GmbH & Co. AKG, ~~copy~~has ofagreed to manufacture one or more application systems pre-filled with an active pharmaceutical ingredient, placebo or other material for the ~~press~~Company. ~~release~~The isCompany ~~furnished~~and Vetter previously entered into a master development agreement, effective as ~~Exhibit~~of ~~99.1~~October 27, to2021, ~~this~~under ~~Current~~which ~~Report~~Vetter onperformed ~~Form~~development ~~8-K~~and manufacturing services related to the Company’s product candidate sonelokimab.

~~This~~The Vetter ~~Item~~MCSA ~~2.02~~is ~~and~~structured as a master agreement under which the ~~press~~parties ~~release~~may ~~attached~~enter ~~hereto~~into asproduct-specific ~~Exhibit~~schedules ~~99.1~~(each, ~~insofar~~a as“Product Schedule”) ~~they~~from ~~disclose~~time ~~information~~to ~~regarding~~time, each detailing the specific manufacturing services and pricing applicable to a particular product. The Company’s ~~results~~has ofagreed ~~operations~~to pay Vetter the prices set forth in each Product Schedule. For each Product Schedule, Vetter may, subject to limitations, adjust its prices based upon reasonable and ~~financial~~documented ~~condition~~information ~~for~~reflecting ~~the~~increases ~~quarter~~in ~~ended~~Vetter’s ~~March 31~~cost structure, including ~~2026~~wages, ~~are~~insurance, ~~being~~energy ~~furnished~~costs toand ~~the~~other ~~U.S.~~associated ~~Securities~~costs and ~~Exchange~~expenses, ~~Commission~~as ~~(“SEC”)~~well as increases in costs of materials supplied or services provided by any third party.

~~Item~~The Vetter 7MCSA shall remain in full force and effect until terminated.01 Either party may terminate the Vetter MCSA or any Product Schedule for cause in the event of a material breach by the other party that has not been cured within 60 calendar days of receiving written notice of such breach. ~~Regulation~~ FDEither ~~Disclosure~~party may also terminate the Vetter MCSA without cause upon 12 months’ written notice, with immediate effect at any time when all existing Product Schedules have been terminated. Vetter may terminate the Vetter MCSA if the Company is the subject of a “Change of Control” (as defined in the Vetter MCSA) by an acquirer that is not a reputable pharmaceutical company meeting certain specified criteria, and the Company may terminate the Vetter MCSA if Vetter is taken over by a competitor of the Company that is active within the sector of development of dermatology and inflammatory diseases, including rheumatology, before the end of 2029. Either party may terminate the Vetter MCSA with immediate effect due to the other party’s bankruptcy or insolvency. The Vetter MCSA includes customary provisions relating to, among others, procedures for defective products, delivery, inspection and acceptance procedures, manufacturing facilities, regulatory matters, intellectual property rights, and confidentiality.

OnAlso on May 1022, 2026, the Company ~~issued~~and Vetter entered into a ~~press~~Capacity ~~release~~Agreement ~~announcing~~(the “Vetter Capacity Agreement”), under which the ~~positive~~Company ~~outcome~~is ~~from~~required to provide Vetter with its ~~final~~aggregate ~~pre-BLA~~demand ~~(Biologics~~for ~~License~~a ~~Application)~~product ~~meeting~~for a certain period, with the ~~U.S.~~annual ~~Food~~demands ~~and~~for ~~Drug~~the initial ~~Administration~~term of such forecast constituting a binding capacity reservation commitment (the “~~FDA~~MoonLake Commitment”),. ~~where~~The ~~the~~MoonLake Commitment ~~Company~~may ~~and~~not ~~the~~be ~~FDA~~increased ~~aligned~~without onVetter’s ~~submission~~prior ~~plans~~written ~~and~~consent (the ~~label~~quantity ~~strategy~~so ~~for~~specified ~~sonelokimab~~being ~~(SLK~~the “Maximum Quantity”) and inmay ~~hidradenitis~~not ~~suppurativa~~be decreased below specified floors (HSthe “Minimum Quantity”). AVetter ~~copy~~has ofcommitted to reserve filling capacity equivalent to the ~~press~~Maximum ~~release~~Quantity isper ~~furnished~~year asfor ~~Exhibit~~the 99agreed binding period.1 The Company may be obligated to ~~this~~pay ~~Current~~capacity ~~Report~~compensation to Vetter if the Company fails to order the Minimum Quantity commitment or fails to provide purchase orders for the agreed binding period. Pursuant to the Vetter Capacity Agreement, the Company may, depending on ~~Form~~the ~~8-K~~timing and amount of reduced aggregate demand, if any, be obligated to pay Vetter for a portion of lost net revenue, subject to certain limitations.

~~This~~The above ~~Item~~descriptions ~~7.01~~of ~~and~~ the ~~press~~Vetter ~~release~~MCSA ~~attached~~and ~~hereto~~Vetter asCapacity ~~Exhibit~~Agreement ~~99.1,~~ are ~~being~~summaries ~~furnished~~only ~~to the SEC~~ and ~~shall~~are ~~not~~qualified bein ~~deemed~~their ~~“filed”~~entirety ~~for~~by ~~purposes~~reference to ~~of Section 18 of~~ the ~~Securities~~Vetter ~~Exchange~~MCSA ~~Act~~and ofVetter ~~1934~~Capacity Agreement, aswhich ~~amended~~will ~~(the~~be ~~“Exchange~~filed ~~Act”),~~as orexhibits ~~otherwise subject~~ to the ~~liabilities~~Company’s ofQuarterly ~~that~~Report ~~section,~~on ~~nor~~Form ~~shall~~10-Q for ~~it be deemed incorporated by reference in any filing under~~ the ~~Exchange~~quarter ~~Act~~ending orJune ~~the Securities Act of 1933~~30, ~~as amended~~2026.

~~Item 9.01. Financial Statements and Exhibits.~~1

(d) Exhibits. The following exhibit is being furnished herewith:

Exhibit Number			Exhibit Title or Description
99.1			Press Release, dated May 10, 2026
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOONLAKE IMMUNOTHERAPEUTICS			~~MOONLAKE IMMUNOTHERAPEUTICS~~
Date:			May 11, 2026	By:	/s/ Matthias Bodenstedt
Date: June 1, 2026	By:	/s/ Matthias Bodenstedt
	Name:	Matthias Bodenstedt		~~Name:~~	~~Matthias Bodenstedt~~
	Title:	Chief Financial Officer		~~Title:~~	~~Chief Financial Officer~~

Filing Compare · MoonLake Immunotherapeutics